FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea - BioSpace
FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea BioSpace
LOUISVILLE, Ky., Aug. 26, 2019 /PRNewswire/ -- US WorldMeds, LLC announced today that the U.S. Food and Drug Administration (FDA) approved the ...
Comments
Post a Comment